Mounjaro Microdose Chart: What the Clinical Evidence Tells Us

What the SURMOUNT trials actually tested, and what they didn't

The appetite for a tirzepatide microdose chart comes, understandably, from people trying to manage side effects or costs. But the clinical programme behind Mounjaro (chiefly the SURMOUNT-1 trial, published in the New England Journal of Medicine) randomised adults to 5mg, 10mg and 15mg weekly doses after an initial 2.5mg lead-in. The 2.5mg lead-in phase was included precisely because researchers recognised the body needs time to adjust; it was never tested as a sustained dose for weight reduction in its own right.

What the programme found at licensed doses was striking: average body-weight reductions of around 20–21% over 72 weeks at the highest dose, across thousands of participants. That evidence base simply does not extend below 2.5mg. There are no published phase-3 data on, say, 1mg or 0.5mg weekly tirzepatide for weight management, which means any chart presenting those amounts as a regime is working from inference, not trial data.

The NICE appraisal of tirzepatide (TA1026) recommends it on the basis of SURMOUNT evidence at licensed doses. Its clinical and cost-effectiveness modelling has no footing below 2.5mg. That is worth holding in mind whenever a chart presents sub-licensed amounts as an established protocol.

Why the idea of microdosing tirzepatide spreads, and where the logic breaks down

The reasoning usually runs like this: GLP-1 and dual-agonist medicines cause nausea, especially early on; lower amounts might cause less nausea; therefore a smaller dose could be a gentler starting point. There is a certain surface logic to it. The problem is that the 2.5mg starting dose in the licensed schedule already embodies exactly that thinking. Eli Lilly designed a four-week 2.5mg lead-in for this reason. The titration schedule (2.5mg, then steps to 5mg, 7.5mg and beyond) was built around tolerability data from the trials themselves.

Going below the licensed floor does not remove risk; it trades known, studied risk for unknown, unstudied risk. You lose the safety net of evidence and gain nothing that the licensed schedule wasn't already trying to provide. The NHS tirzepatide medicines page sets out the expected side-effect profile for the licensed doses; no equivalent NHS or MHRA resource exists for sub-licensed amounts, because no such resource can.

There is also a practical issue with the KwikPen format. Each pen delivers a fixed dose via a pre-set mechanism. Attempting to draw a partial dose introduces variables in measurement that a syringe-and-vial setup might at least make visible, with a pre-filled auto-injector, those variables are largely invisible. Accuracy matters with any medicine; with one where dose determines both tolerability and effect, accuracy matters considerably.

What microdose charts can and cannot tell you about cost and pen stretching

A related motivation is financial. If you are wondering what Mounjaro costs privately, you are not alone, it is one of the most common questions our prescribers receive. Eli Lilly's UK list price for higher-dose pens rose significantly from September 2025, and private prices now vary widely. The logic of stretching a pen by taking less each week is understandable, particularly if a large order arrives just before a holiday or your prescription renewal lands at an awkward point in the month.

But splitting doses across weeks changes your dosing interval and your weekly exposure in ways that have not been tested. The pharmacokinetics of tirzepatide (how it builds and clears in your body) were studied on a strict once-weekly schedule. Altering that schedule, even with the same total volume per pen, is not equivalent to the studied regime. Your prescriber is the right person to discuss cost concerns with; there may be clinical options (titration pace, dose hold, switching) that are both safer and more effective than self-adjusting the amount.

If you are exploring what tirzepatide involves more broadly, the tirzepatide overview covers the mechanism and licensed indications in full. For a closer look at the specific practice this type of chart is usually describing, our page on microdosing Mounjaro examines the concept in detail, and if you want to understand how microdose Mounjaro approaches are being discussed and used in practice, that page sets out the context clearly, while what a microdose of tirzepatide actually means addresses the terminology directly.

How a prescriber approaches dose, and why that is different from a chart

A microdose chart, however detailed it looks, cannot know your medical history, your current medications, your kidney function, or whether you have a background condition that affects how you tolerate GLP-1 activity. A GPhC-registered Independent Prescriber reviewing your consultation at nume (sorry, at our pharmacy) is doing exactly that. They read your answers the same day, check for contraindications, and make a clinical judgement about where to start and how to progress.

That process is what separates a licensed prescription from a chart someone assembled from forum posts. The tirzepatide dosing for weight loss page explains what the licensed titration path looks like in practice, which is the clinically grounded answer to most of the questions these charts are trying to address. If questions about your own plan remain, a prescriber is the right source. You can check your eligibility and start a free consultation with our clinical team; a real prescriber, not automated software, will review your case.